SunRegen Healthcare was announced as the winner of the BIO-Europe® 2018 Startup Slam competition, held in Copenhagen. Dr Yuhong Dong, Director and co-founder of SunRegen presented how the company’s therapeutic is a potentially transformative healthcare solution for neurodegenerative eye diseases. More details were published in PR Newwire.
SunRegen attracted the eyes of investors and won strong support from industry and academia scientists. On the first anniversary, SunRegen closed its seed round financing to move ahead on the promising project for the treatment of neurological disorders.
In August, SunRegen founder team presented their SBC003 project in the CTI coaching acceptance meeting. The jury acknowledged the high potential value in the market for treatments of neurodegenerative disorders. Swiss CTI decided to continue to support SunRegen and to offer professional coaching, executed by Dr. Andreas J. Schulze.
In order to encourage research collaboration with Swiss research groups, CTI provided an innovation grant to SunRegen to collaborate with the Brain Mind Institute (BMI) in École polytechnique fédérale de Lausanne (EPFL). The collaboration with EPFL will greatly expand the research capability of SunRegen.
SunRegen SBC003 project was accepted as a phase I project by BaseLaunch, which is a healthcare accelerator backed by Novartis, Pfizer, Johnson & Johnson, and Roche. (please visit BaseLaunch portfolio.).
After a thorough evaluation of SunRegen’s business plan, Swiss Commission for Technology and Innovation (CTI) decided to offer CTI coaching phase 2 to SunRegen. CTI coach Dr. Andreas J. Schulze started to provide professional coaching support for SunRegen.